Processing

Please wait...

Settings

Settings

1. WO2018083105 - PYRIDAZINE DERIVATIVES AS RORC MODULATORS

Publication Number WO/2018/083105
Publication Date 11.05.2018
International Application No. PCT/EP2017/077931
International Filing Date 31.10.2017
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50
Pyridazines; Hydrogenated pyridazines
502
ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17
Drugs for dermatological disorders
06
Antipsoriatics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
C07D 401/14 (2006.01)
C07D 405/14 (2006.01)
C07D 413/14 (2006.01)
C07D 403/14 (2006.01)
C07D 409/14 (2006.01)
A61K 31/502 (2006.01)
CPC
A61K 31/502
A61K 31/505
A61P 17/06
A61P 37/00
C07D 401/14
C07D 403/14
Applicants
  • F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124 4070 Basel, CH (AllExceptUS)
  • GENENTECH, INC. [US/US]; 1 DNA Way South San Francisco, California 94080, US (US)
Inventors
  • BRONNER, Sarah M.; US
  • CRAWFORD, James J.; US
  • CRIDLAND, Andrew; GB
  • CYR, Patrick; CA
  • FAUBER, Benjamin; US
  • GANCIA, Emanuela; GB
  • GOBBI, Alberto; US
  • HURLEY, Christopher; GB
  • KILLEN, Jonathan; GB
  • LEE, Wendy; US
  • RENE, Olivier; US
  • VAN NIEL, Monique Bodil; GB
  • WARD, Stuart; GB
  • WINSHIP, Paul; GB
  • ZBIEG, Jason; US
Agents
  • BERNARD, Guillaume; CH
Priority Data
62/415,90501.11.2016US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PYRIDAZINE DERIVATIVES AS RORC MODULATORS
(FR) DÉRIVÉS DE PYRIDAZINE UTILISÉS EN TANT QUE MODULATEURS DE RORC
Abstract
(EN)
Compounds of formula (I): (I) or pharmaceutical salts thereof, wherein m, n,, p, q A, B, Ri, R2, R3, R4, R5, R6and R7are as defined herein. Also disclosed are methods of making the compounds and using the compounds as RORs modulators for treatment of inflammatory diseases such as arthritis.
(FR)
L'invention concerne des composés de formule (I) : (I) ou des sels pharmaceutiquement acceptables de ceux-ci, dans laquelle m, n, p, q, A, B, Ri, R2, R3, R4, R5, R6 et R7 sont tels que définis dans la description. L'invention concerne également des procédés de préparation des composés et l'utilisation des composés en tant que modulateurs de ROR pour le traitement de maladies inflammatoires telles que l'arthrite.
Also published as
MXMX/a/2019/005090
RU2019115791
Latest bibliographic data on file with the International Bureau